Abstract
The Charlson Comorbidity Index plus three comorbidity scales were evaluated for survival after radiochemotherapy of limited stage SCLC. For the Charlson Comorbidity Index, 2–4 points were compared to 5–8 points. For the Age-Comorbidity Score, 2–6 points were compared to 7–10 points. For the Medical Research Council (MRC) Breathlessness Scale, grades 0–2 were compared to grades 3–5. For the Simplified Comorbidity Score, 0–5 points were compared to 6–11 and 12–17 points. Charlson Comorbidity Index (p = 0.022) and MRC Breathlessness Scale (p < 0.001) showed significant associations with survival, the Age-Comorbidity Score a trend (p = 0.06). For the Simplified Comorbidity Score, no significant correlation was found (p = 0.54). Absolute differences in survival ≥20 % were observed for the MRC Breathlessness Scale at 1, 2, and 3 years, for the Charlson Comorbidity Index at 1 year, and for the Age-Comorbidity Score at 2 years. Thus, particularly the MRC Breathlessness Scale can contribute to personalization of the treatment of SCLC.
This is a preview of subscription content, log in via an institution to check access.
References
Jeremic B, Dobric Z, Casas F (2011) Limited-disease small-cell lung cancer. In: Jeremic B (ed) Advances in radiation oncology in lung cancer, 2nd edn. Springer, Heidelberg, pp 491–506
Iachina M, Jakobsen E, Moller H et al (2015) The effect of different comorbidities on survival of non-small cell lung cancer patients. Lung 193:291–297
Firat S, Byhardt RW, Gore E, Radiation Therapy Oncology Group (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 54:357–364
Kopek N, Paludan M, Petersen J et al (2009) Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 93:402–407
Simon TG, Beland MD, Machan JT et al (2012) Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. Eur J Radiol 81:4167–4172
Otake S, Ohtsuka T, Asakura K et al (2016) Impact of comorbidity index on morbidity and survival in non-small cell lung cancer. Asian Cardiovasc Thorac Ann 24:30–33
Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Charlson M, Szatrowski TP, Peterson J et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251
Stenton C (2008) The MRC breathlessness scale. Occup Med (Lond) 58:226–227
Colinet B, Jacot W, Bertrand D et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93:1098–1105
Gazula A, Baldini EH, Chen A et al (2014) Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung 192:151–158
Razi SS, Lebovics RS, Schwartz G et al (2010) Timely airway stenting improves survival in patients with malignant central airway obstruction. Ann Thorac Surg 90:1088–1093
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Rights and permissions
About this article
Cite this article
Kaesmann, L., Janssen, S., Schild, S.E. et al. Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer. Lung 194, 295–298 (2016). https://doi.org/10.1007/s00408-016-9857-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-016-9857-4